TScan Therapeutics Announces Board and Executive Changes

Ticker: TCRX · Form: 8-K · Filed: 2025-08-20T00:00:00.000Z

Sentiment: neutral

Topics: management-change, executive-compensation, board-of-directors

TL;DR

TScan Therapeutics shakes up its board and exec pay structure as of Aug 14, 2025.

AI Summary

TScan Therapeutics, Inc. announced on August 14, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel.

Why It Matters

Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and stock performance.

Risk Assessment

Risk Level: medium — Board and executive changes can indicate internal shifts or strategic realignments that may carry inherent risks.

Key Numbers

Key Players & Entities

FAQ

What specific roles have been affected by the departure of directors or officers?

The filing indicates the departure of 'certain officers' and 'directors' but does not specify individual names or roles in this section.

Who are the newly elected directors?

The filing states that directors have been elected but does not name the individuals in this excerpt.

What are the key changes in compensatory arrangements for officers?

The filing notes changes to 'Compensatory Arrangements of Certain Officers' but does not provide specific details on the nature of these changes.

What is the exact date of the reported events?

The date of the earliest event reported is August 14, 2025.

Where are TScan Therapeutics' principal executive offices located?

The principal executive offices are located at 830 Winter Street, Waltham, Massachusetts 02451.

From the Filing

0001193125-25-184083.txt : 20250820 0001193125-25-184083.hdr.sgml : 20250820 20250820161034 ACCESSION NUMBER: 0001193125-25-184083 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250814 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250820 DATE AS OF CHANGE: 20250820 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 251236898 BUSINESS ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 d55649d8k.htm 8-K 8-K false 0001783328 0001783328 2025-08-14 2025-08-14     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2025     TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)   Delaware   001-40603   82-5282075 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   830 Winter Street Waltham , Massachusetts   02451 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code 857 399-9500 Not Applicable (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Voting Common Stock, par value $0.0001 per share   TCRX   The Nasdaq Global Market, LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐       Item 5.02. Appointment of Certain Officers. On August 14, 2025, the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) appointed Leiden Dworak, Vice President, Finance of the Company, as the Company’s Principal Accounting Officer, effective August 14, 2025. Upon the effectiveness of such appointment, Jason A. Amello ceased to serve as the Company’s Principal Accounting Officer, but Mr. Amello continues to serve as the Company’s Chief Financial Officer and Principal Financial Officer. Mr. Dworak, age 41, ha

View on Read The Filing